Immuneering (IMRX) Net Equity Issued and Repurchased (2020 - 2025)
Immuneering (IMRX) posted quarterly Net Equity Issued and Repurchased of $1081.0 for Q4 2025, down 97.11% year-over-year from $37397.0 in Q4 2024, and down 99.92% quarter-over-quarter from $1.3 million in Q3 2025.
Immuneering (IMRX) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Immuneering's Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $1081.0 for Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased fell 97.11% year-over-year to $1081.0; the TTM figure through Mar 2026 stood at $1.3 million (down 92.74% YoY), while the FY2025 annual figure was $25.0 million, up 489.98% from the prior year.
- Net Equity Issued and Repurchased for Q4 2025 stood at $1081.0, down from $1.3 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $95.5 million in Q3 2021, with the low at -$28.2 million in Q4 2023.
- The 4-year median for Net Equity Issued and Repurchased is $1.3 million (2025), against an average of $12.4 million.
- The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased jumped 100.13% in 2024, then slumped 97.11% in 2025.
- Immuneering's Net Equity Issued and Repurchased stood at $95.5 million in 2021, then slumped by 129.52% to -$28.2 million in 2023, then jumped by 100.13% to $37397.0 in 2024, then plunged by 97.11% to $1081.0 in 2025.
- Business Quant data shows IMRX's Net Equity Issued and Repurchased at $1081.0 in Q4 2025, $1.3 million in Q3 2025, and $13.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,081.00 |
| Dec 31, 2025 | 1,081.00 |
| Sep 30, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 13.68 Mn |
| Mar 31, 2025 | 13.68 Mn |
| Dec 31, 2024 | 37,397.00 |
| Dec 31, 2024 | 37,397.00 |
| Sep 30, 2024 | 4.20 Mn |
| Sep 30, 2024 | 4.20 Mn |
| Dec 31, 2023 | -28.20 Mn |
| Dec 31, 2023 | -28.20 Mn |
| Sep 30, 2021 | 95.53 Mn |
| Sep 30, 2021 | 95.53 Mn |
| Dec 31, 2020 | 37.20 Mn |
| Dec 31, 2020 | 37.20 Mn |